Announcement
Thank you for attending THSNA 2026. The virtual meeting is now closed.
Thank you for attending THSNA 2026. The virtual meeting is now closed.
Presentation Details
| Perioperative Hemostatic Strategies in Total Knee Arthroplasty for Hemophilia: A Systematic Evidence Review of Bleeding, Factor Use, and Thrombotic Risk Jack Russek1, Angad Thakral2. 1Touro University California, Vallejo, CA, USA.2Touro University California, Vallejo, CA, USA |
Abstract
Background
Total knee arthroplast (TKA) is increasingly used for advanced hemophilic arthropathy but remains high stakes from a hemostatic standpoint. Historically, perioperative bleeding, high factor consumption, infection, and stiffness were common, while pharmacologic thromboprophylaxis is often avoided because of bleeding risk. Contemporary protocols incorporating pharmacokinetic guided factor replacement and tranexamic acid (TXA) may have improved outcomes, yet integrated data on bleeding, factor use, and venous thromboembolism remain limited. Objectives
To synthesize modern TKA outcomes in adults with hemophilia A or B, focusing on perioperative blood loss, major bleeding, transfusion, effects of tranexamic acid and pharmacokinetic guided factor replacement on factor utilization, and symptomatic venous thromboembolism under predominantly mechanical prophylaxis. Methods
A targeted PubMed search (1980–2025) identified English-language clinical studies reporting outcomes of primary TKA in adults with hemophilia. Eligible studies included case series, cohorts, and trials reporting bleeding volume, major bleeding, transfusion, factor dosing strategies, tranexamic acid use, or venous thromboembolism. Data were extracted on TXA route and dose, factor replacement protocols, bleeding and transfusion metrics, venous thromboembolism events, and complications. Heterogeneity in design and reporting required descriptive synthesis. Results
Across more than twenty contemporary series including over five hundred procedures, mean total blood loss generally ranged from nine hundred to twelve hundred milliliters, with drain outputs near five to seven hundred milliliters and hemoglobin decreases of two to four grams per deciliter. In mixed arthroplasty cohorts, major bleeding occurred in about thirty percent of cases, although postoperative hemarthrosis specific to TKA was typically five to ten percent. Comparative studies showed that combined intravenous and intraarticular TXA reduced blood loss by roughly five hundred milliliters and lowered transfusion rates, for example nineteen percent compared with sixty one percent, while reducing factor eight use by approximately fourteen percent. Intraarticular tranexamic acid alone was associated with near elimination of transfusion without excess thrombosis. Antifibrinolytic use overall correlated with reduced major bleeding. Pharmacokinetic guided or in vivo recovery guided factor replacement strategies, reported in about one quarter of studies, targeted eighty to one hundred percent activity at surgery with tapering through postoperative days one to fourteen. These approaches maintained hemostasis, reduced hidden blood loss in enhanced recovery pathways, and in at least one study lowered factor use by about twenty percent without increasing venous thromboembolism. Symptomatic venous thromboembolism after TKA in hemophilia was rare. Many series reported no events, and others reported rates of one to three percent despite frequent avoidance of pharmacologic prophylaxis. Reported periprosthetic joint infection rates were usually two to seven percent, and stiffness requiring manipulation or arthrolysis ranged from seven to thirty five percent, especially in patients with limited preoperative motion. Conclusions
Modern TKA for hemophilia can be performed with acceptable bleeding outcomes and very low symptomatic venous thromboembolism when guided by structured factor replacement and antifibrinolytic strategies. TXA reduces blood loss, transfusion, and factor usage, and pharmacokinetic tailored regimens further optimize dosing. Future studies should standardize bleeding definitions, quantify factor sparing, and refine algorithms integrating tranexamic acid, individualized factor replacement, and selective thromboprophylaxis.
No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author.
Total knee arthroplast (TKA) is increasingly used for advanced hemophilic arthropathy but remains high stakes from a hemostatic standpoint. Historically, perioperative bleeding, high factor consumption, infection, and stiffness were common, while pharmacologic thromboprophylaxis is often avoided because of bleeding risk. Contemporary protocols incorporating pharmacokinetic guided factor replacement and tranexamic acid (TXA) may have improved outcomes, yet integrated data on bleeding, factor use, and venous thromboembolism remain limited. Objectives
To synthesize modern TKA outcomes in adults with hemophilia A or B, focusing on perioperative blood loss, major bleeding, transfusion, effects of tranexamic acid and pharmacokinetic guided factor replacement on factor utilization, and symptomatic venous thromboembolism under predominantly mechanical prophylaxis. Methods
A targeted PubMed search (1980–2025) identified English-language clinical studies reporting outcomes of primary TKA in adults with hemophilia. Eligible studies included case series, cohorts, and trials reporting bleeding volume, major bleeding, transfusion, factor dosing strategies, tranexamic acid use, or venous thromboembolism. Data were extracted on TXA route and dose, factor replacement protocols, bleeding and transfusion metrics, venous thromboembolism events, and complications. Heterogeneity in design and reporting required descriptive synthesis. Results
Across more than twenty contemporary series including over five hundred procedures, mean total blood loss generally ranged from nine hundred to twelve hundred milliliters, with drain outputs near five to seven hundred milliliters and hemoglobin decreases of two to four grams per deciliter. In mixed arthroplasty cohorts, major bleeding occurred in about thirty percent of cases, although postoperative hemarthrosis specific to TKA was typically five to ten percent. Comparative studies showed that combined intravenous and intraarticular TXA reduced blood loss by roughly five hundred milliliters and lowered transfusion rates, for example nineteen percent compared with sixty one percent, while reducing factor eight use by approximately fourteen percent. Intraarticular tranexamic acid alone was associated with near elimination of transfusion without excess thrombosis. Antifibrinolytic use overall correlated with reduced major bleeding. Pharmacokinetic guided or in vivo recovery guided factor replacement strategies, reported in about one quarter of studies, targeted eighty to one hundred percent activity at surgery with tapering through postoperative days one to fourteen. These approaches maintained hemostasis, reduced hidden blood loss in enhanced recovery pathways, and in at least one study lowered factor use by about twenty percent without increasing venous thromboembolism. Symptomatic venous thromboembolism after TKA in hemophilia was rare. Many series reported no events, and others reported rates of one to three percent despite frequent avoidance of pharmacologic prophylaxis. Reported periprosthetic joint infection rates were usually two to seven percent, and stiffness requiring manipulation or arthrolysis ranged from seven to thirty five percent, especially in patients with limited preoperative motion. Conclusions
Modern TKA for hemophilia can be performed with acceptable bleeding outcomes and very low symptomatic venous thromboembolism when guided by structured factor replacement and antifibrinolytic strategies. TXA reduces blood loss, transfusion, and factor usage, and pharmacokinetic tailored regimens further optimize dosing. Future studies should standardize bleeding definitions, quantify factor sparing, and refine algorithms integrating tranexamic acid, individualized factor replacement, and selective thromboprophylaxis.
No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author.